CFR Chemaphor Inc.

Chemaphor Inc. (TSX VENTURE: CFR), today announced that its Avivagen Animal Health subsidiary is nearing commercial launch of its proprietary Oximunol™ Chewable Tablets for dogs and its VetStem RC regenerative cell treatment. Chemaphor has achieved the following milestones since its press release of October 1, 2010:

--  Avivagen Animal Health, Chemaphor's animal health commercialization
    subsidiary, has selected a specialized advertising and communications
    agency and has developed the creative concepts and materials needed in
    support of the launch of Avivagen's products and services;
--  Sales representatives have been hired and trained to discuss Avivagen
    Oximunol™ Chewable Tablets and VetStem RC with veterinarians in
    companion animal clinics, initially in Quebec, Ontario and British
    Columbia;
--  Supporting the outreach effort to veterinarians in companion animal
    clinics outside the major metropolitan areas as well as pet parents is
    our newly hired Avivagen Animal Health marketing communications
    associate who will be responsible for supporting our social media
    activities;
--  Selected an Ontario-based, FDA-registered pharmaceutical manufacturing
    facility to manufacture Oximunol™ Chewable Tablets and to act as a
    distribution facility for the product;
--  Avivagen Animal Health sales representatives will begin visiting
    veterinarians on November 8, 2010;
--  Shipment of Oximunol™ Chewable Tablets is scheduled to begin November
    15, 2010; and
--  Aligned our core management and executive team - Dr. Graham Burton takes
    on the role of Managing Director of Research Co-Ordination in addition
    to his role as President, while Dr. Janusz Daroszewski steps out of the
    role of Chief Scientific Officer and into the role of Managing Director
    of Chemistry and Technical Support.

Dave Hankinson, CEO of Chemaphor and Avivagen commented that "these are exciting days at Avivagen as we prepare to have our products and services on the market in just a few weeks and to be interacting directly with veterinarians across Canada with new solutions offered to pets and pet owners for managing day-to-day enjoyment. We are proud to bring on new staff and are enjoying our collaboration with our new corporate partners."

Chemaphor also announced that, effective as of November 4, 2010, Mark Goudie has left the Chemaphor board of directors.

Amin Khalifa, Chairman of the board added "I am pleased to see the rapid progress in our animal health organization - Avivagen - and the spirit of collaboration that we have been able to foster. I would also like to thank Mark Goudie on behalf of the company and the board for his significant contributions to Chemaphor's growth, and for his financial leadership and assistance in establishing good corporate governance and controls. We wish him well in his future endeavours."

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products to humans and animals to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various, potential human applications. More information can be found at www.chemaphor.com.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon current expectations, which involve risks and uncertainties associated with Chemaphor's business and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", and similar expressions to the extent they relate to Chemaphor or its management. The forward-looking statements are not historical facts, but reflect Chemaphor's current expectations regarding future results or events. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Chemaphor assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contacts: Chemaphor Inc. Graham Burton 613-990-0969 g.burton@chemaphor.com Investor Relations Evolution Group Inc. Sylvain Archambault President 1-866-703-4887 s.archambault@evolutiongrp.com